SEQ-400
SEQ-400 is a vaccine against urinary [tract infection]s which is under development for potential medical use. It is a vaccine against the Escherichia coli FimH adhesin protein, which is essential for bacterial infection. The vaccine is being developed by Sequoia Sciences. As of September 2023, it is in Phases of [clinical research#Phase II|phase 2] clinical trials. SEQ-400 is being developed for potential approval and use in the United States.